53297-73-7

Basic information

• Product Name: Acetamide, N-[4-(aminosulfonyl)-2-chlorophenyl]-2-chloro-
• CAS NO: 53297-73-7
• Molecular Formula: C8H8Cl2N2O3S
• Molecular Weight: 283.135
• Mol File: 53297-73-7.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Acetamide, N-[4-(aminosulfonyl)-2-chlorophenyl]-2-chloro-(CAS DataBase Reference)
• NIST Chemistry Reference: Acetamide, N-[4-(aminosulfonyl)-2-chlorophenyl]-2-chloro-(53297-73-7)
• EPA Substance Registry System: Acetamide, N-[4-(aminosulfonyl)-2-chlorophenyl]-2-chloro-(53297-73-7)

Safety Data

• Hazardous Substances Data: 53297-73-7(Hazardous Substances Data)

Upstream product

• 53297-68-0 4-amino-3-chlorobenzenesulfonamide 
• 79-04-9 chloroacetyl chloride 
• 16761-18-5 4-acetamido-3-chlorobenzenesulphonyl chloride 
• 68252-72-2 4-acetamido-3-chlorobenzenesulfonamide 

Downstream Products

• 53297-96-4 2-(p-Chloroanilino)-N-(2-chloro-4-sulphamoylphenyl)-acetamide 
• 53297-97-5 2-(p-Methoxyanilino)-N-(2-chloro-4-sulphamoylphenyl)-acetamide 
• 53297-95-3 2-Cyclohexylamino-N-(2-chloro-4-sulphamoylphenyl)-acetamide 
• 53298-03-6 2-(p-Methylanilino)-N-(2-chloro-4sulphamoylphenyl)-acetamide 
• 1562665-99-9 C₂₃H₂₁ClN₄O₅S₃ 
• 1562665-86-4 2-{[1-(3,5-dimethylbenzyl)-1H-benzimidazol-2-yl]sulfanyl}-N-(2-chloro-4-sulfamoylphenyl)acetamide 
• 1562666-11-8 C₂₃H₂₀Cl₂N₄O₅S₃ 
• 1562665-93-3 2-{[6-chloro-1-(3,5-dimethylbenzyl)-1H-benzimidazol-2-yl]sulfanyl}-N-(2-chloro-4-sulfamoylphenyl)acetamide 
• 878672-13-0 C₁₉H₁₈Cl₂N₆O₃S₂ 
• 878672-10-7 C₂₄H₂₃ClN₆O₃S₂ 
• 878672-06-1 C₂₄H₂₃ClN₆O₄S₂ 
• 878671-97-7 2-[5-amino-4-(4-cyclopropylnaphthalen-1-yl)-4H-[1,2,4]triazol-3-ylsulfanyl]-N-(2-chloro-4-sulfamoylphenyl)acetamide 
• 53297-74-8 2-Phenylamino-N-(2-chloro-4-sulphamoylphenyl)-acetamide 
• 53297-98-6 2-(3-Methylanilino)-N-(2-chloro-4-sulphamoylphenyl)-acetamide 

Relevant articles and documents

Structural optimization of N1-aryl-benzimidazoles for the discovery of new non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are recommended components of preferred combination antiretroviral therapies used for the treatment of human immunodeficiency virus (HIV) infection. These regimens are extremely effective in suppressing virus replication. Recently, our research group identified some N1-aryl-2-arylthioacetamido-benzimidazoles as a novel class of NNRTIs. In this research work we report the design, the synthesis and the structure–activity relationship studies of new compounds (20–34) in which some structural modifications have been introduced in order to investigate their effects on reverse transcriptase (RT) inhibition and to better define the features needed to increase the antiviral activity. Most of the new compounds proved to be highly effective in inhibiting both RT enzyme at nanomolar concentrations and HIV-1 replication in MT4 cells with minimal cytotoxicity. Among them, the most promising N1-aryl-2-arylthioacetamido-benzimidazoles and N1-aryl-2-aryloxyacetamido-benzimidazoles were also tested toward a panel of single- and double-mutants strain responsible for resistance to NNRTIs, showing in vitro antiviral activity toward single mutants L100I, K103N, Y181C, Y188L and E138K. The best results were observed for derivatives 29 and 33 active also against the double mutants F227L and V106A. Computational approaches were applied in order to rationalize the potency of the new synthesized inhibitors.

Tri-substituted triazoles as potent non-nucleoside inhibitors of the HIV-1 reverse transcriptase

A new series of 1,2,4-triazoles was synthesized and tested against several NNRTI-resistant HIV-1 isolates. Several of these compounds exhibited potent antiviral activities against efavirenz- and nevirapine-resistant viruses, containing K103N and/or Y181C mutations or Y188L mutation. Triazoles were first synthesized from commercially available substituted phenylthiosemicarbazides, then from isothiocyanates, and later by condensing the desired substituted anilines with thiosemicarbazones.

Sulphamoylphenyl-imidazolidinones

N-Sulphamoylphenyl-substituted imidazolidin-4-ones having useful anti-epileptic activity are prepared by cyclising N-sulphamoylphenyl-substituted α-aminoacetamides with formaldehyde or a reactive derivative of carbonic acid, or by reacting N-halosulphonylphenyl-substituted imidazolidin-4-ones with ammonia.